Insulet upgraded by Wolfe Research with a new price target
$PODD
Medical/Dental Instruments
Health Care
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2025 | $350.00 | Peer Perform → Outperform | Wolfe Research |
| 4/29/2025 | Outperform → Peer Perform | Wolfe Research | |
| 3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
| 12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. "At Insulet, our sustainability impact is inextricably tied to our mission as a company and our workplace culture. Through our products and innovative business models, we can make life simpler for millions of people with diabetes while improving health outcomes," said Vice President of Global
Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P
Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig
Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
4 - INSULET CORP (0001145197) (Issuer)
3 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00
Wolfe Research downgraded Insulet from Outperform to Peer Perform
RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00
Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210
Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
8-K - INSULET CORP (0001145197) (Filer)
DEF 14A - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)